Nyxoah S.A. Overview
| Field | Detail |
|---|---|
| Legal name | Nyxoah SA (société anonyme / naamloze vennootschap under Belgian law) |
| Former names | None publicly disclosed |
| Founded | 2009 (founded by Robert Taub, current Chairman) |
| Incorporation jurisdiction | Belgium |
| Registered office / HQ | Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (per SEC Form 6-K cover, June 2026) |
| Primary listing | Euronext Brussels — NYXH (since September 2020) |
| Secondary listing | Nasdaq Global Market — NYXH (since July 2021) |
| Other trading venues | Stuttgart (5YI), among other German venues — unofficial secondary trading |
| ISIN | BE0974358906 |
| CUSIP | Not publicly disclosed in sources reviewed (Nasdaq line trades as ordinary shares, not ADSs) |
| SEC filer status | Foreign private issuer; files Form 20-F (annual) and Form 6-K (current/quarterly); CIK 0001857190 |
| Fiscal year end | 31 December |
| Employees | not publicly disclosed in sources reviewed. Directionally, the U.S. sales organisation grew from 25 to 40 field representatives in Q1 2026, with a plan to reach 55 territories in H2 2026 |
| Auditor | Not re-verified for FY2025 in this research cycle (historically a Big Four firm's Belgian practice; confirm against the 20-F) |
| Market capitalisation (current) | About USD 98M at USD 0.96 intraday on 19 October 2026, after a ~13% fall on the guidance cut (Stock Titan); about USD 113M at the USD 1.11 close on 16 October 2026 (Yahoo Finance) |
| Shares outstanding | 101,840,217 as of 25 August 2026, per a company share-capital notice cited by a third-party tracker; later convertible-bond share settlements may have added to this |
| Website | www.nyxoah.com |
| Investor relations | IR@nyxoah.com — Rémi Renard, Head of IR & Corporate Communication |
| CEO | Liam Kelly (effective 1 October 2026; former Chairman, President & CEO of Teleflex) |
| Interim CFO | Loïc Moreau (President International; interim CFO from 2 October 2026) |
| Chairman | Robert Taub (founder) |
The entity profiled is the same listed company identified in the request: Nyxoah SA, the Belgian parent of the Nyxoah group. The listing details supplied are current. No name change or listing migration has occurred. Since July 2021 the company has been dual-listed on Euronext Brussels and the Nasdaq Global Market, both under the ticker NYXH.
Nyxoah is a Belgian medical technology company that has built a single, differentiated therapy platform for obstructive sleep apnea (OSA). Its Genio system is a hypoglossal nerve stimulation (HGNS) implant that stimulates both branches of the hypoglossal nerve. The implant is small, leadless and battery-free, and it is powered each night by an external activation chip worn on a disposable adhesive patch under the chin. Genio has carried a CE Mark since 2019 and won U.S. FDA PMA approval on 8 August 2025. Nyxoah is therefore the first credible U.S. challenger to Inspire Medical Systems, which has held an effective monopoly in HGNS. The company's thesis rests on four features: bilateral stimulation, full-body MRI compatibility, no implanted battery that must be replaced surgically, and a potential label extension to complete concentric collapse (CCC) patients, who are contraindicated for Inspire. It remains loss-making and dependent on capital markets. Its near-term value depends on how fast U.S. adoption ramps, on reimbursement clarity, and on patent litigation with Inspire.
Company's own description
In its FY2025 Form 20-F, Nyxoah describes itself as a medical technology company focused on developing and commercialising innovative OSA treatments. It calls its lead solution, Genio, a CE-Marked, patient-centric, minimally invasive, next-generation hypoglossal neurostimulation therapy for moderate to severe OSA. The company frames OSA as the world's most common sleep-disordered breathing condition, associated with higher mortality risk and comorbidities such as cardiovascular disease, depression and stroke. It describes Genio as a first-of-its-kind HGNS device that uses bilateral stimulation to keep the airway open during sleep. (Source: Form 20-F, FY2025.)
The company began generating revenue from Genio sales in Europe in July 2020. It reports that its main sources of capital to date have been private placements, public equity offerings, debt financing and product revenue. (Source: Form 20-F, FY2025.)
Independent characterisation
| Revenue component | Nature | Disclosure status |
|---|---|---|
| Implantable stimulator + surgical kit | One-time capital-like product sale per procedure, billed to hospital / ambulatory surgery centre (ASC) | — |
| External activation chip / charging unit | One-time device sale bundled with the system | — |
| Disposable adhesive patches | Recurring consumable, recognised over the delivery period (deferred revenue) | Partially visible via deferred revenue: €1.0M deferred in FY2025, €0.3M in Q1 2026 |
| Services / subscription / licensing | None material | Not applicable |
Nyxoah is a single-product, single-indication, implant-plus-disposables business. Its economics resemble an active implantable neuromodulation company, such as a spinal cord stimulation or cochlear implant maker, with one important difference: Genio has a recurring consumables component. Each patient needs a steady supply of disposable adhesive patches to attach the external activation chip. That creates a modest annuity tail. Under IFRS 15 this tail forces revenue deferral, because patches delivered over time are recognised over time.
Revenue model mix (analyst characterisation; not segment-disclosed):
Value-chain position: Nyxoah designs the device and controls final assembly and quality in Mont-Saint-Guibert, Belgium. In January 2023 it entered a collaboration with Cochlear Limited to transfer assets and support the set-up of a U.S. production line (Source: Q3 2025 interim report, 6-K/A). Distribution is direct in the U.S., Germany and other core European markets, and goes through distributors in the Middle East.
Customer types: The paying customers are hospitals and ASCs, which buy the system and bill payers. The clinical decision-makers are ENT/sleep surgeons, with referral flowing from sleep physicians. Reimbursement comes from Medicare (U.S. facility C-codes C8011–C8013 established February 2026), commercial insurers (CPT codes for HGNS implantation, with prior authorisation required) and European statutory systems (Germany's DRG system, the UK NHS Specialised Services Devices Programme, and others).
End market: Moderate-to-severe OSA in adults who fail or cannot tolerate positive airway pressure (PAP/CPAP) therapy. This is the "second-line" OSA market that Inspire created and still dominates.
The clinical/regulatory foundation
| Study | Purpose | Key outcome | Status |
|---|---|---|---|
| BLAST OSA | European CE Mark study | Supported CE Mark (2019) | Completed |
| BETTER SLEEP | Bilateral stimulation incl. CCC patients (Australia/Europe) | Supported CE Mark extension to CCC patients | Completed |
| DREAM (U.S. IDE pivotal) | FDA PMA support | Met primary endpoints (announced 19 March 2024); published in Journal of Clinical Sleep Medicine. Labelling reflects efficacy in both supine and non-supine positions (per Q4 2025 earnings call) | Completed; PMA approved 8 August 2025 |
| ACCCESS (U.S. pivotal, CCC) | U.S. label expansion to CCC patients; FDA Breakthrough Device Designation | 12-month AHI responder rate 77.2% (Sher criteria, p<0.001); ODI responder rate 87.7% (p<0.001); zero device-related serious adverse events; n=47 implanted | Topline 2 September 2026; full data at ISSS 15–16 October 2026; PMA supplement submitted (disclosed 19 October 2026) |
| BREATHE (U.S. post-approval study) | FDA-mandated PAS | First patient implanted 7 September 2026 | Enrolling |
| European PMCF (NCT04031040) | Long-term post-market follow-up | Registry primary completion estimate 30 October 2026 | Ongoing |
The U.S. label covers moderate-to-severe OSA with an apnea-hypopnea index (AHI) of 15 to 65 (FDA approval, 8 August 2025). The treatment of CCC patients currently appears in the warnings section of the U.S. indications for use (company boilerplate, October 2026).
Strategy
Stated strategy (themes from the FY2025 20-F, earnings calls and the July 2026 Investor Day)
Management's strategy rests on five themes (paraphrased from company disclosures):
-
Win in the United States. The U.S. is the centre of the growth strategy. Leadership has been "Americanised" (U.S.-based CEO from October 2026), the sales force is expanding from 40 to 55 territories in H2 2026, and the company targets high-volume HGNS accounts, with 233 active by end-Q3 2026.
-
Differentiate on patient-centric design. Bilateral stimulation, no implanted battery, full-body MRI compatibility, upgradability without re-surgery, and efficacy regardless of sleep position.
-
Expand the addressable population. Pursue the CCC indication in the U.S. (ACCCESS; PMA supplement filed October 2026) and grow European reimbursement country by country.
-
Secure reimbursement. Use the Medicare C-codes (C8011–C8013) and existing commercial CPT codes. The company chose not to seek a dedicated Category I CPT code at the September 2026 CPT panel and instead supports a comprehensive coding approach for all AGNS devices led by specialty societies such as AAO-HNS.
-
Improve unit economics. Launch the Genio 2.2 patch/activation chip in early 2027 to cut disposable costs; raise manufacturing yields and overhead absorption; take gross margin from about 60% to the mid-60s and higher.
Initiatives in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| U.S. commercial launch | August 2025 onward | Direct sales, surgeon training, account activation, prior-authorisation support | Ongoing; 342 surgeons trained, 233 accounts |
| Sales force expansion | Q1 2026 / H2 2026 | +15 reps and 3 sales directors in Q1 2026 (40 reps); expansion to 55 territories in H2 2026 | Under way; drives Q4 2026 opex step-up |
| ACCCESS CCC programme | 2024–2026 | U.S. pivotal in CCC under Breakthrough Device Designation | Endpoints met; PMA supplement submitted October 2026 |
| BREATHE post-approval study | September 2026 | FDA-required U.S. PAS | First patient implanted |
| Genio 2.2 | Target early 2027 | Next-gen disposable patch and activation chip; cost reduction | In development |
| Reimbursement engagement | 2,026 | CMS C-codes (Feb 2026); proposed 2027 OPPS (+12%) and ASC (+15%) increases for the Genio procedure | Final 2027 rule expected around November 2026 |
| Leadership transition | June–October 2026 | U.S.-based CEO | Completed (Kelly) |
| Recapitalisation | June 2026 | USD 95M equity plus USD 15M EIB tranche | Completed |
| Intellectual property enforcement | September–December 2025 | Countersuit in Delaware; UPC actions in Munich | Ongoing |
| International expansion | 2024–2025 | UK (NHS SSDP), Middle East, Netherlands | Completed entries |
Sustainability/ESG commitments: no quantified ESG targets were found in the sources reviewed.
Cost programmes: none announced. The company is in an investment phase, with opex guided up to €99–102M in FY2026.
Management guidance and medium-term targets
| Metric | Guidance | Date issued | Status |
|---|---|---|---|
| FY2026 global net revenue | €33–35M | 19 October 2026 | Lowered from €36–40M (issued with Q4 2025 results / Q1 2026; reaffirmed in August and on 21 September 2026) |
| FY2026 gross margin | 60–62% | Q1 2026; reaffirmed 21 September 2026 | Current; H2 2026 expected at 63–64% |
| FY2026 total operating expenses | €99–102M | Reaffirmed 21 September 2026 (raised at Q2 per Stock Titan's Q2 summary) | Current |
| Q4 2026 U.S. growth | Improving sequential U.S. growth vs Q3 | 19 October 2026 | Current |
| Implied Q4 2026 revenue | €9.7–11.7M (analyst derivation: guidance less €23.3M nine-month revenue) | — | Derived |
| Medium-term targets (revenue, profitability timing) | A path to profitability was discussed at the July 2026 Investor Day | 8 July 2026 | Not publicly verified |
Products & Services
Nyxoah sells a single product family. The catalog below breaks Genio into its components and generations.
Genio system (current commercial generation)
| Attribute | Detail |
|---|---|
| Product | Genio® hypoglossal nerve stimulation system |
| Indication (EU) | Moderate to severe OSA, including CCC patients (CE Mark extension after BETTER SLEEP) |
| Indication (U.S.) | Moderate to severe OSA, AHI 15–65 (FDA PMA, 8 August 2025); CCC currently in label warnings; PMA supplement for CCC filed October 2026 |
| Mechanism | Bilateral stimulation of both hypoglossal nerve branches to protrude the tongue and keep the upper airway open during sleep |
| Implant | Small, leadless, battery-free neurostimulator placed under the chin through a single submental incision; electrodes contact both hypoglossal nerve branches |
| Power | External activation chip on a disposable adhesive patch worn nightly; energy transferred wirelessly |
| Key claimed advantages | No implanted battery (no battery-replacement surgery); full-body MRI compatibility; upgradable external electronics without re-surgery; bilateral stimulation; single incision; efficacy in supine and non-supine positions per U.S. labelling |
| Components | Implantable stimulator; activation chip; charging unit; disposable adhesive patches; physician programming tools |
| Target customer | ENT/sleep surgeons at high-volume HGNS centres (hospitals and ASCs); patients intolerant of CPAP |
| Launch | EU 2019 (CE Mark), first revenue July 2020; U.S. August 2025 |
| Pricing model | Per-procedure system price plus recurring disposables; list prices not publicly disclosed. U.S. Medicare hospital outpatient payment for C8011 is USD 31,526 in 2026, with a CMS proposal of USD 35,414 for 2027 (+12%); the proposed ASC increase is about 15% |
| Versioning | The current generation is referred to as Genio 2.1 in company materials (per prior disclosures); next generation below |
Genio 2.2 (next-generation disposable patch / activation chip — in development)
| Attribute | Detail |
|---|---|
| Description | Next-generation disposable patch and activation chip |
| Rationale | Better patient experience and a significant cut in disposable patch cost, which should lift gross margin |
| Timing | Launch expected in early 2027 (per the then-CFO on the Q4 2025 earnings call, 19 March 2026) |
| Financial impact | Management guided a larger gross-margin step-up in early 2027 from Genio 2.2 |
Pipeline indications / label expansions
| Programme | Status | Commercial relevance |
|---|---|---|
| CCC indication (U.S.) | ACCCESS met endpoints; PMA supplement submitted under Breakthrough Device Designation (19 October 2026) | Opens patients who cannot receive Inspire therapy because of CCC on drug-induced sleep endoscopy |
| Long-term outcomes (BREATHE, PMCF) | Ongoing | Supports payer coverage and durability claims |
Services
Nyxoah offers no stand-alone service lines. Its surgeon training, account activation and patient-access support (help with prior authorisation) are commercial enablement activities, not revenue-generating services.
Financial Narrative
Data quality statement
FY2023–FY2025 figures come from the company's annual results releases and the FY2025 20-F. Cells left blank were not publicly verified during this research and are not estimated. EBITDA is not reported by the company.
Income statement
Sources: FY2024 results release (13 March 2025): revenue €4.5M after €0.6M deferral (underlying €5.1M); COGS €1.5M; FY2023 COGS €1.7M and gross margin 62%; R&D €34.3M vs €26.7M; SG&A €28.5M vs €21.7M; operating loss €58.8M vs €45.1M; total comprehensive loss €58.459M vs €43.251M. FY2025 results release (19 March 2026) and 20-F: gross revenue €11.0M, net revenue €10.0M, operating loss €83.5M. The FY2025 net loss of about €90.1M appears in the 20-F (rounded to €90.0M) and on Stock Analysis (€90.09M, +52.1% vs FY2024), which implies a FY2024 net loss of about €59.2M.
EPS, dividends, EBITDA:
Basic and diluted EPS are identical for a loss-making company. Yahoo Finance shows trailing-twelve-month EPS of about USD -2.56 as of October 2026 (aggregator). EBITDA is not reported and not computed. It is deeply negative, roughly approximated by the operating loss plus D&A.
Margin profile
FY2024 gross margin is derived as (4.5 − 1.5)/4.5. The company reported a Q4 2024 gross margin of 73%. Q1 2025 was 62% and Q2 2025 was 63% (6-K).
Revenue CAGR: FY2021–FY2025 ≈ 88% per year (€0.8M → €10.0M). FY2023–FY2025 ≈ 52% per year. Both are computed from the table above. The base is small, which inflates these rates.
Quarterly bridge — the U.S. launch inflection
Sources: Q1 2025, H1 2025 and 9M 2025 interim reports (6-K); Q4/FY2025 release; Q1 2026 and Q2 2026 releases; preliminary Q3 2026 release (19 October 2026, unaudited). Q3 2025 global revenue is derived as 9M €4.4M minus H1 €2.4M. U.S. Q3 2025 revenue was €231,000. Q2 2025 net loss is derived as H1 €43.0M minus Q1 €22.4M. Q3 2025 net loss is derived as 9M €66.6M minus H1 €43.0M. Q2 2026 net loss is derived as H1 €48.9M minus Q1 €15.9M. U.S. Q4 2025 is €3.4M per the Q1 2026 call; the preliminary release had indicated about €3.5M. International figures are derived. The Q3 2026 split is preliminary.
Commentary. The income statement has two regimes. From 2021 to mid-2025 Nyxoah was a European-only business with flat revenue of about €1–1.3M per quarter. Spending rose sharply as it funded DREAM, the PMA submission and U.S. launch preparation: operating loss widened from €45.1M (FY2023) to €58.8M (FY2024). After the FDA approval in August 2025, U.S. revenue went from zero to €6.7M per quarter within five quarters. Sequential U.S. growth was 25% in Q1 2026, 22% in Q2 and 29% in Q3. Even so, the quarterly operating loss has stayed stuck at about €20M. Commercial build-out (SG&A up from about €11–12M to about €15.5M per quarter) has absorbed every incremental euro of gross profit.
Gross margin fell from the low 60s to 57% in Q1 2026. Management blamed the higher U.S. revenue mix and production yields, and guided a recovery to 63–64% in H2 2026 and a further step-up with Genio 2.2 in 2027. FY2026 operating expense guidance of €99–102M (reaffirmed 21 September 2026) implies a sharp Q4 step-up as the U.S. sales force grows from 40 to 55 territories.
The FY2025 net loss of €90.1M was worse than the operating loss of €83.5M. The gap came from negative financial results: USD depreciation, interest on the EIB loan, and fair-value movements on the EIB synthetic warrants and, later, the convertible bond. In H1 2026 the net financial result was a €7.0M charge. Of that, €5.4M came from fair-value losses on the convertible bond and synthetic warrant liabilities, and €1.5M from amortisation of the day-one loss on the convertible.
Balance sheet
Sources: FY2024 release (cash and financial assets €85.6M vs €57.7M; cash and equivalents €34.186M); FY2025 release and 20-F (cash €30.0M, financial assets €18.0M, long-term debt €19.0M, accumulated deficit €306.0M — these appear rounded in the 20-F overview text). FY2024 financial assets are derived. Nyxoah has made no acquisitions, so it carries no acquisition goodwill. Capitalised development costs are the main intangible and were not quantified here.
Debt instruments outstanding (as of mid-October 2026, from filings):
Net debt / net cash (analyst derivation, nominal values): At 31 December 2025, cash and financial assets of €48.0M against nominal borrowings of about €32.5M (EIB €10.0M plus convertible €22.5M) implied net cash of about €15.5M. At 30 June 2026, cash of €97.8M against about €42M of nominal debt (including Tranche B and after partial convertible amortisation) implied net cash of roughly €55M. These are derivations, not company-reported metrics. IFRS carrying values differ because the convertible and warrants are carried at fair value.
Cash flow
Q3 2026 burn was about €20.8M (€97.8M → €77.0M; preliminary). Annualised, that is about €80–85M, before the guided Q4 opex step-up.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (As Reported) Overview
| Segment (as reported) | Contents | Products |
|---|---|---|
Single segment — OSA neuromodulation | All revenue, cost and assets | Genio system (implant, activation chip, disposable patches, programming/charging equipment) |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Segment net revenue (EUR Mn) | 4.3 | 4.5 | 10.0 |
YoY growth (%) | 39 | 5 | 122 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Operating loss (EUR Mn) | -45.1 | -58.8 | -83.5 |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
U.S. net revenue (EUR Mn) | 0.0 | 0.0 | 3.7 |
International net revenue (EUR Mn) | 4.3 | 4.5 | 6.3 |
U.S. share of total (%) | 0 | 0 | 37 |
Group Entities
| Entity | Jurisdiction | Function |
|---|---|---|
Nyxoah SA | Belgium | Parent, HQ, manufacturing, R&D, listed entity |
Nyxoah, Inc. | United States | U.S. commercial operations; co-defendant in Inspire litigation |
Other subsidiaries (Israel R&D, Australia clinical, European sales entities) | Various | — |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net revenue (EUR Mn) | 0.8 | 3.1 | 4.3 | 4.5 | 10.0 |
Gross revenue before patch deferral (EUR Mn) | — | — | 4.3 | 5.1 | 11.0 |
Cost of goods sold (EUR Mn) | — | — | 1.7 | 1.5 | — |
Gross profit (EUR Mn) | — | — | 2.7 | 3.0 | — |
R&D expense (EUR Mn) | — | — | 26.7 | 34.3 | — |
SG&A expense (EUR Mn) | — | — | 21.7 | 28.5 | — |
Operating income (EUR Mn) | — | — | -45.1 | -58.8 | -83.5 |
Net income (EUR Mn) | — | — | -43.2 | -59.2 | -90.1 |
Total comprehensive loss (EUR Mn) | — | — | -43.3 | -58.5 | — |
Financial Analysis
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Gross margin (%) | 62 | 67 | — |
Operating margin (%) | -1,049 | -1,307 | -835 |
Net margin (%) | -1,005 | -1,316 | -901 |
Income Statement and Margin Analysis (%)
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|---|---|
Global net revenue (EUR Mn) | 1.1 | 1.3 | 2.0 | 5.6 | 6.4 | 7.7 | 9.2 |
U.S. net revenue (EUR Mn) | 0.0 | 0.0 | 0.2 | 3.4 | 4.3 | 5.2 | 6.7 |
International net revenue (EUR Mn) | 1.1 | 1.3 | 1.8 | 2.2 | 2.1 | 2.5 | 2.5 |
Gross margin (%) | 62 | 63 | — | — | 57 | 60 | — |
R&D expense (EUR Mn) | 9.0 | 10.1 | — | 10.9 | 8.8 | 9.5 | — |
SG&A expense (EUR Mn) | 12.4 | 10.7 | — | 12.5 | 15.4 | 15.6 | — |
Operating loss (EUR Mn) | -20.6 | -19.9 | — | -18.6 | -20.5 | -20.6 | — |
Net loss (EUR Mn) | -22.4 | -20.6 | -23.6 | — | -15.9 | -33.0 | — |
Cash + financial assets, period end (EUR Mn) | 63.0 | 43.0 | 22.5 | 48.0 | 25.9 | 97.8 | 77.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansKey Financials
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Cash + current financial assets (EUR Mn) | 57.7 | 85.6 | 48.0 |
Cash & cash equivalents (EUR Mn) | — | 34.2 | 30.0 |
Financial assets / term deposits (EUR Mn) | — | 51.4 | 18.0 |
Long-term debt (EUR Mn) | — | — | 19.0 |
Accumulated deficit (EUR Mn) | — | — | 306.0 |
Capital Instruments
| Instrument | Counterparty | Principal | Terms | Status |
|---|---|---|---|---|
EIB venture loan — Tranche A | European Investment Bank | €10.0M | Part of €37.5M facility (July 2024); InvestEU-backed; no revenue or liquidity covenants; 20-year synthetic warrants granted to EIB | Drawn (2024) |
EIB venture loan — Tranche B | European Investment Bank | €13.75M (received as about €13.8M / USD 15M) | Same facility | Drawn June 2026 |
EIB venture loan — Tranche C | European Investment Bank | €13.75M | Subject to conditions | Undrawn as of last disclosure |
Convertible bonds — Tranche 1 | Entity managed by Heights Capital Management | €22.5M nominal (225 bonds × €100k) | 6.5% coupon; 3-year amortising to 2028; quarterly principal of €8,500 per bond, settleable in shares under certain conditions; senior unsecured | Issued 18 December 2025; amortising, partly settled in shares (e.g., 1,767,402 shares issued around August 2026, per a third-party tracker of company notices) |
Convertible bonds — Tranche 2 | HCM | Up to €22.5M | Optional; substantially the same terms | Drawdown not confirmed in sources reviewed |
Balance Sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Change in cash + financial assets (EUR Mn) | — | 27.9 | -37.6 |
Equity raised, gross (EUR Mn) | — | 48.5 | 17.0 |
Debt raised, gross (EUR Mn) | — | 10.0 | 22.5 |
Dividends paid (EUR Mn) | 0 | 0 | 0 |
Share buybacks (EUR Mn) | 0 | 0 | 0 |
Financial Analysis (FY2025 value)
| Ratio | FY2025 value | Comment |
|---|---|---|
ROE | NM (negative) | — |
ROA | NM (negative) | — |
ROIC | NM (negative) | — |
Current ratio | Not computed | Liquidity dominated by cash/term deposits |
Debt / equity | Not computed | — |
Asset turnover | Very low | Revenue €10.0M |
Cash runway (analyst view) | About 3–4 quarters at the Q3 2026 burn rate from €77.0M, before any Tranche C/convertible Tranche 2 drawdown and before revenue growth | Implies a likely return to capital markets during 2027 unless burn falls |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
United States net revenue (EUR Mn) | 0.0 | 0.0 | 3.7 |
International (Europe + Middle East) net revenue (EUR Mn) | 4.3 | 4.5 | 6.3 |
Total net revenue (EUR Mn) | 4.3 | 4.5 | 10.0 |
International YoY growth (%) | 39 | 5 | 40 |
Revenue by Region
| Region | H1 2025 | H1 2026 | Q3 2026 (prelim.) |
|---|---|---|---|
United States (EUR Mn) | 0.0 | 9.5 | 6.7 |
International (EUR Mn) | 2.4 | 4.5 | 2.5 |
Total (EUR Mn) | 2.4 | 14.0 | 9.2 |
Country / Market Details
| Country / market | First revenue | Channel | Notes |
|---|---|---|---|
Germany | 2,020 | Direct | Largest European market; break-even reached H1 2026; ResMed Germany partnership |
Other initial EU markets | 2020–2023 | Direct | Specific early markets per prior filings |
Austria, Spain, Italy | Disclosed as revenue-generating by 2025 | Direct/hybrid | Reimbursement dossiers pending in additional countries |
United Kingdom | Q4 2024 | NHS SSDP | — |
UAE (Dubai) | Q1 2025 | Distributor | First Middle East market |
Kuwait, Abu Dhabi | Q2 2025 | Distributor | — |
Netherlands | Q4 2025 | Direct | — |
United States | Q3 2025 | Direct | 233 active high-volume accounts and 342 trained surgeons by end-Q3 2026 |
Share Price & Returns
| Reference point | Price (USD) | Date | Source |
|---|---|---|---|
Nasdaq IPO | 30.00 | 2 July 2021 | MarketBeat |
Start of 2025 | 8.00 | 1 January 2025 | MarketBeat |
FDA approval | about 7.28 | 8 August 2025 | MobiHealthNews |
October 2025 | 6.10 | 8 October 2025 | MarketBeat |
52-week high (to early October 2026) | 6.875 | Q4 2025 | Stock Analysis |
May 2026 | 2.99 | 1 May 2026 | Fintel |
Offering price | 1.72 | 5 June 2026 | Company |
Pre-Q2 results | 1.43 | 29 July 2026 | MarketBeat |
Early October 2026 | 1.36 | 2 October 2026 | Stock Analysis |
Last close before guidance cut | 1.11 | 16 October 2026 | Yahoo Finance |
Intraday after guidance cut | about 0.96 | 19 October 2026 | Stock Titan (15-minute delayed) |
Return metric | NYXH | Basis | — |
1-year return (%) | about -84 | From about USD 6.10 (October 2025) to about USD 0.96 (analyst derivation) | — |
3-year return (%) | Not computed | — | — |
5-year / since Nasdaq IPO (%) | about -97 | From USD 30.00 (July 2021) to about USD 0.96 | — |
Valuation Multiples
| Multiple | NYXH | Comment |
|---|---|---|
EV/Sales (FY2026E guidance midpoint €34M ≈ USD 39M) | about 1.4x | Market cap about USD 98M, less net cash of roughly USD 40–50M (Q3 2026 cash €77.0M less about €40M nominal debt), gives EV of about USD 50–60M. Analyst derivation; very approximate |
P/B | about 1.5x (aggregator, mid-2026; pre-raise book) | Gurufocus; stale |
Analyst Ratings & Targets
| Broker | Rating | Price target (USD) | Date |
|---|---|---|---|
Cantor Fitzgerald (Sarah James) | Overweight | 6.00 (from 11.00) | 17 August 2026 |
Piper Sandler (Adam Maeder) | Overweight | 6.00 (from 7.00; earlier cut from 9.00 to 7.00 on 13 May 2026) | Post-Q2 2026 |
Oppenheimer | Outperform | 4.00 (from 13.00) | August 2026 |
Stifel | Hold (downgraded from Buy earlier) | 3.00 (from 5.00) | 17 June 2026 |
Baird | Neutral | 2.31 (from 2.85; earlier 4.00 → 2.85 on 9 July 2026) | Post-Q2 2026 |
Consensus | "Buy" (Stock Analysis, 4 analysts) / "Hold" (MarketBeat) | about 4.2–4.4 | October 2026 (aggregators) |
Capital Markets
| Item | Status |
|---|---|
Dividend history | None paid; no dividend expected (accumulated deficit €306M at end-2025) |
Dividend policy | Retain all earnings to fund operations |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Shares outstanding | 101,840,217 (25 August 2026) vs 34,360,390 earlier in the cycle (TipRanks notice) and about 37.4M (2025) |
Share capital | €7,073,687.00 (latest notice per aggregator) |
Capital Instruments — HCM convertible Tranche 1
| Instrument | Principal | Maturity | Amortisation |
|---|---|---|---|
HCM convertible Tranche 1 | €22.5M nominal (amortising) | December 2028 | Quarterly €1.9125M (€8,500 × 225 bonds), final €1.4625M; may be share-settled |
EIB Tranche A | €10.0M | — | — |
EIB Tranche B | €13.75M | As above | — |
EIB Tranche C | €13.75M (undrawn) | — | Conditional |
Analyst Conclusions
Management guidance (current)
| Item | Guidance |
|---|---|
| FY2026 net revenue | €33–35M (lowered 19 October 2026) |
| Q4 2026 U.S. growth | Sequential growth expected to improve vs Q3's 29% |
| FY2026 gross margin | 60–62% |
| FY2026 operating expenses | €99–102M |
| 2027 margin driver | Genio 2.2 disposable patch launch (early 2027) |
| Regulatory | FDA review of the CCC PMA supplement (Breakthrough designation) |
Consensus growth expectations: Formal post-cut consensus was not available at the time of writing. Pre-cut aggregator data showed multi-year revenue CAGR expectations above 100% from a small base (AlphaSpread), which are now likely to be revised down.
Bull case (3 arguments)
-
The adoption curve is intact; only the slope was mis-forecast. U.S. revenue grew 29% sequentially in Q3 2026. Accounts rose from 180 to 233 in one quarter, and 447 patients are in prior authorisation. Each newly activated account should deepen utilisation over 12–24 months. The guidance cut reflects timing, not demand.
-
A CCC approval would create a defensible niche. With a 77.2% AHI responder rate and zero device-related SAEs in a population Inspire cannot treat, a CCC label would give Nyxoah exclusive access to a meaningful slice of DISE-screened patients. It would also strengthen the wider "choice" narrative.
-
Valuation is near cash-adjusted distress. At about USD 100M market capitalisation, with roughly €77M of gross cash and a run-rate of about €37M+ in annual revenue, EV/Sales is roughly 1–1.5x. That is extremely low for a growing, FDA-approved implant platform. Reimbursement increases (+12–15% in 2027), Genio 2.2 margin expansion and a seasoned CEO from Teleflex could prompt a re-rating or attract strategic interest.
Bear case (3 arguments)
-
Unit economics and funding do not yet work. Quarterly operating losses of about €20M on €7–9M revenue, gross margin of about 60%, and opex guided to rise imply roughly €80M+ of annual burn. Cash of €77.0M implies another dilutive raise within about 12 months, at a share price below USD 1.
-
Litigation could prove existential. The IPRs were denied, the Markman hearing is imminent, and a December 2027 jury trial is scheduled. An adverse outcome against an incumbent with far greater resources could bring an injunction or royalties that cripple U.S. economics.
-
The category itself is under pressure. Inspire's U.S. revenue is declining in 2026 on coding and prior-authorisation disruption. GLP-1/GIP drugs could shrink the surgical pool. Nyxoah's external wearable may cap patient preference. The company has cut guidance and changed CEO and CFO within months, which hurts management credibility.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | Why it matters |
|---|---|---|
| 29 October 2026 | Markman hearing, Inspire v. Nyxoah (consolidated) | Claim scope shapes infringement and validity risk |
| About November 2026 | CMS final 2027 OPPS/ASC rule | Confirms the proposed +12% / +15% payment increases |
| 5 November 2026 | Full Q3 2026 results | Gross margin, opex trajectory, cash burn detail, new CEO's priorities |
| Q4 2026 | Delivery of €9.7–11.7M implied Q4 revenue | Tests the revised guidance |
| Late 2026 – 2027 | Nasdaq minimum bid price compliance | A deficiency notice is possible if shares stay below USD 1.00 |
| H1 2027 | FDA decision on the CCC PMA supplement | Label expansion |
| Early 2027 | Genio 2.2 launch | Gross-margin step-up |
| 2,027 | Financing (EIB Tranche C, convertible Tranche 2, equity) | Dilution and runway |
| Ongoing | Account productivity (revenue per active account), surgeon training, PA approval rate | Leading indicators of the ramp |
| Ongoing | UPC Munich proceedings vs Inspire | European IP leverage |
| Ongoing | AGNS CPT coding outcome (AMA/specialty societies) | Physician payment clarity |
Concluding analyst verdict
Nyxoah has done the hardest thing a medical device start-up can do: it has won FDA approval for a differentiated implant and launched it against an entrenched incumbent. The clinical case is sound. DREAM supported approval, and ACCCESS has now produced a 77.2% responder rate with no device-related serious adverse events in CCC patients, a population Inspire cannot treat. The commercial leading indicators are moving the right way. Active U.S. accounts rose from 91 to 233 and trained surgeons from 207 to 342 within two quarters, and U.S. revenue grew 29% sequentially in Q3 2026.
The investment debate, however, is no longer about whether Genio works. It is about time and money. The October 2026 guidance cut shows that utilisation per account is building more slowly than management modelled. Meanwhile the cost base is still rising toward €99–102M a year and gross margin sits near 60% until Genio 2.2 arrives in 2027. With €77.0M of cash and roughly €20M of quarterly burn, Nyxoah will probably need more capital in 2027, and the share price below USD 1 makes any raise highly dilutive. The Inspire litigation is a binary overlay: the Markman hearing on 29 October 2026 and the December 2027 trial could either neutralise or seriously impair the U.S. franchise.
Liam Kelly's appointment is the most important qualitative positive. He brings proven scaling discipline from Teleflex, but his first act was resetting expectations, and he has no permanent CFO. Our synthesis: Nyxoah is a high-risk, high-optionality turnaround of a sound technology. Its valuation now discounts significant failure risk. Investors with tolerance for dilution and litigation risk may find asymmetric upside, from a CCC approval, reimbursement increases, margin expansion or strategic interest. More conservative investors should wait for evidence of operating leverage, ideally a quarterly operating loss falling below €15M, and for clarity on claim construction before committing capital.
Data caveats: Preliminary Q3 2026 figures are unaudited and subject to revision. Aggregator data (share counts, ownership, market capitalisation, consensus) varies between sources and should be checked against company transparency notifications and SEC filings. Blank cells in multi-year tables indicate data not publicly verified in this research cycle, not zero values. Items marked "analyst derivation" are arithmetic computations from disclosed figures, not company-reported metrics.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation |
|---|---|---|---|---|
Liam Kelly | Chief Executive Officer | Since 1 October 2026 | Chairman (from May 2020), President and CEO (from January 2018) of Teleflex until January 2026; joined Teleflex in 2009, roles included President EMEA, President International, President Americas, COO | Not yet disclosed (appointment post-dates the FY2025 20-F) |
Loïc Moreau | President International and Interim CFO | Joined 2022 as CFO; President International since 2024; interim CFO from 2 October 2026 | Corporate finance background | — |
Olivier Taelman | Former CEO (2019–30 September 2026) | About 7 years | Led Nyxoah from clinical stage through FDA approval | — |
John Landry | Former CFO | Left 2 October 2026 | Departed for another opportunity | — |
Rémi Renard | Head of IR & Corporate Communication | — | — | — |
Board of Directors
| Director | Role | Independence | Background |
|---|---|---|---|
Robert Taub | Chairman; founder | Non-independent (founder; related party for the June 2026 offering) | Co-founded and co-managed Octapharma for 12 years; founded Omrix Biopharmaceuticals (Nasdaq IPO, acquired by J&J) |
Kevin Rakin | Director (since June 2016) | Treated as related party for the June 2026 offering (participation via controlled entities) | Co-founder of HighCape Partners; former Chairman/CEO of Advanced BioHealing (sold to Shire, 2011); co-founder/CEO of Genaissance Pharmaceuticals; MBA Columbia; degrees from the University of Cape Town |
Jürgen Hambrecht | Director | Treated as related party for the June 2026 offering | About 45 years at BASF, finally Chairman of its Supervisory Board 2014–2020; Chairman of Trumpf's Supervisory Board |
Rita Johnson-Mills | Independent director; chairs the Nominating & Governance Committee | Independent | Former market CEO at Centene and UnitedHealthcare; former CMS Medicaid managed care oversight; boards incl. Owens & Minor; NACD Directorship 100 honoree (2025) |
Virginia Kirby | Independent director | Independent | Member of the independent committee that reviewed the June 2026 related-party offering participation |
Wildman Ventures, LLC (represented by Daniel Wildman) | Independent director | Independent | Long J&J career (Digital Surgery Strategy, DePuy Synthes Spine, Ethicon Biosurgery); Chairman of Progenerative Medical; UroGen Pharma board |
Olivier Taelman | Executive director (historical) | Non-independent | Board status after stepping down as CEO not confirmed |
Liam Kelly | — | — | Board appointment not confirmed in sources reviewed |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
| 2024 | Loïc Moreau moves from CFO to President International | U.S.-focused finance leadership brought in pre-launch |
4 June 2026 | Board launches search for a U.S.-based CEO; Taelman to remain through the transition | Positioned as accelerating the U.S. launch; announced alongside the USD 95M offering |
21 September 2026 | CFO John Landry resigns effective 2 October 2026; Moreau appointed interim CFO; FY2026 guidance reaffirmed | Second senior departure within four months |
28 September 2026 | Liam Kelly appointed CEO effective 1 October 2026 | Highly credentialed U.S. medtech CEO |
19 October 2026 | Kelly's first public communication is a guidance cut | Kelly attributed the slower ramp to typical new-technology adoption curves |
Major Shareholders
| Holder | Stake | Source / date | Comment |
|---|---|---|---|
Insiders (aggregate) | About 17% (pre-June 2026 offering) | MarketBeat (2025) | Founder- and board-linked holdings; insiders participated in the June 2026 offering, so the current percentage may differ |
Vestal Point Capital LP | About 6.8% (2025) | MarketBeat (April 2025) | Holding may have changed; a Schedule 13G/A was filed 14 August 2026 (filer not confirmed here) |
Competitive Landscape
Key Competitors
| # | Competitor | Category | Product(s) | Relative positioning vs Nyxoah |
|---|---|---|---|---|
| 1 | Inspire Medical Systems (NYSE: INSP) | HGNS — direct | Inspire V (5th generation), Inspire IV | Dominant incumbent with about USD 0.8–0.9bn revenue; vast installed base and surgeon network; unilateral stimulation with implanted battery; CCC contraindicated. Facing its own 2026 coding/reimbursement disruption |
| 2 | LivaNova (aura6000 / ex-ImThera) | HGNS — direct (pipeline) | aura6000 proximal HGNS (OSPREY trial) | Pursuing U.S. approval per 2026 industry commentary; potential third entrant |
| 3 | ResMed | PAP — first-line therapy (also a Nyxoah partner) | AirSense CPAP devices, masks, digital health | First-line standard of care; feeds the CPAP-failure pool HGNS addresses |
| 4 | Philips Respironics | PAP | DreamStation | Diminished U.S. presence after its device recall; still relevant outside the U.S. |
| 5 | Fisher & Paykel Healthcare | PAP interfaces | Masks, humidification | PAP ecosystem |
| 6 | Eli Lilly | Pharmacological | Zepbound (tirzepatide), FDA-approved for moderate-to-severe OSA in adults with obesity (December 2024) | Structural threat: weight loss lowers AHI and could shrink or delay the HGNS-eligible population; also possibly complementary (bringing BMI into HGNS range) |
| 7 | Apnimed | Pharmacological (pipeline) | AD109 (oral combination) | — |
| 8 | Oral appliance makers (e.g., SomnoMed, ProSomnus) | Mandibular advancement devices | Custom oral appliances | Alternative for mild-to-moderate OSA |
| 9 | Vivos Therapeutics | Oral appliance / airway remodelling | DNA/mRNA appliances | Niche alternative |
| 10 | Surgical alternatives (UPPP, MMA, TORS) | Procedures | Soft-tissue and skeletal surgery | Legacy alternatives with higher morbidity |
Peer Comparison FY2026
| Metric | Nyxoah | Inspire Medical |
|---|---|---|
Latest annual revenue | €10.0M (FY2025) | About USD 0.91bn (FY2025, implied from FY2026 initial guidance of USD 1,003–1,013M at +10–11%) |
Current-year outlook | €33–35M FY2026 | USD 835–875M FY2026 (raised in August 2026 from 825–875; cut in May from about 1,003–1,013) |
Growth | +122% FY2025; FY2026 guide implies about +230–250% | Q2 2026 revenue -7.6% YoY; Q3 2026 guided -8% to -10% YoY |
Gross margin | 60% (Q2 2026) | — |
Operating margin | Deeply negative (Q2 2026 operating loss €20.6M on €7.7M revenue) | Adjusted operating margin guided 4–6% FY2026 |
R&D intensity | More than 100% of revenue | — |



